ERAS Stock Overview
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Erasca, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.04 |
| 52 Week High | US$12.80 |
| 52 Week Low | US$3.60 |
| Beta | 0 |
| 1 Month Change | -6.26% |
| 3 Month Change | -49.56% |
| 1 Year Change | -65.91% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.82% |
Recent News & Updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20
Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Recent updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28Shareholder Returns
| ERAS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | 0.8% | 2.8% |
| 1Y | -65.9% | 7.1% | -9.2% |
Return vs Industry: ERAS underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ERAS underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| ERAS volatility | |
|---|---|
| ERAS Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ERAS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ERAS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 123 | Jonathan Lim | https://www.erasca.com |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme.
Erasca, Inc. Fundamentals Summary
| ERAS fundamental statistics | |
|---|---|
| Market Cap | US$606.22m |
| Earnings (TTM) | -US$138.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs ERAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERAS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$138.02m |
| Earnings | -US$138.02m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ERAS perform over the long term?
See historical performance and comparison